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Glucocorticoids (GCs), which act on stress pathways, are well-established in the co-treatment of different kinds
of tumors; however, the underlying mechanisms by which GCs act are not yet well elucidated. As such, this
work investigates the role of glucocorticoids, speciﬁcally dexamethasone (DEXA), in the processes referred to as
DNA damage and DNA damage response (DDR), establishing a new approach in three astrocytomas cell lines
(CT2A, APP.PS1 L.1 and APP.PS1 L.3). The results show that DEXA administration increased the basal levels of
gamma-H2AX foci, keeping them higher 4 h after irradiation (IR) of the cells, compared to untreated cells. This
means that DEXA might cause increased radiosensitivity in these cell lines. On the other hand, DEXA did not
have an apparent effect on the formation and disappearance of the 53BP1 foci. Furthermore, it was found that
DEXA administered 2 h before IR led to a radical change in DNA repair kinetics, even DEXA does not affect cell
cycle. It is important to highlight that DEXA produced cell death in these cell lines compared to untreated cells.
Finally and most important, the high levels of gamma-H2AX could be reversed by administration of ascorbic
acid, a potent blocker of reactive oxygen species, suggesting that DEXA acts by causing DNA damage via oxi-
dative stress. These exiting ﬁndings suggest that DEXA might promote radiosensitivity in brain tumors, spe-
ciﬁcally in astrocytoma-like tumors.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
Glucocorticoids (GCs) such as dexamethasone (DEXA) are
widely known for their anti-inﬂammatory properties, and are
used, as such, in the treatment of inﬂammatory disorders such
asthma [1], rheumatoid arthritis [2] and autoimmune diseases [3].
Moreover, GCs are commonly used as co-medications in cancer
therapy [4] due to their effectiveness in treating the secondary
effects of the cancer treatments, including inﬂammation, pain,
edema, anorexia, and nauseas [4,5].
These GCs are not only given during chemotherapy treatment
but also before and after, depending on the procedure and dose,
which may vary for different kinds of tumors. Regardless of the
procedure used, the ultimate goal of GC treatment is to reduce
acute toxicity in cancer patients, thus offering protection against
the long-term effects of genotoxic drugs [5].
Despite the extended use of the GCs, its pro- and anti-apoptotic
effects, which depend on the cell type, have only been partially
described in recent years. It is known that GCs induce apoptosisB.V. This is an open access article u
rticoids; IR, Irradiation; DDR,
ining pathway; DSBs, double
ralocorticoid receptor.
gy, Åbo Akademi Universitymainly in cells of the hematological lineage, as well as in some
non-hematologic cells such osteoblasts. GCs promote survival in
several non-hematologic tissues, such as gliomas, mammary
glands, ovaries, livers, and ﬁbroblasts [6]. In addition, it is known
that GCs may have anti- or pro-apoptotic effects within an iden-
tical cell type, depending on different external circumstances [7,8].
The most common glucocorticoid prescribed for brain tumors
is DEXA [9,10], a synthetic steroidal glucocorticoid. The reason for
widespread use of DEXA is its long biological half-life and its low
mineralocorticoid activity (sodium retaining) [2]. This GC acts by
decreasing the permeability of the blood–brain barrier and low-
ering regional cerebral blood volume, leading to subsequent im-
provement in the symptoms of chemotherapy patients [6]. In ad-
dition, DEXA may counteract the actions of vascular endothelial
growth factor (VEGF) by decreasing edema in the brain tumor [11].
However, not all data obtained from the use of DEXA in brain
tumors patients have been positive. In fact, doctors must now
weigh the beneﬁcial effects of this treatment in patients with brain
tumors against the possibility that it may reduce the efﬁcacy of
chemotherapy drugs that act by inducing apoptosis. In this regard,
it has been reported that DEXA pre-treatment may interfere with
apoptotic death in brain tumor cells via the transcriptional acti-
vation of a Bcl-xL gene [6]. Indeed, patients treated with the
combination of 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) and ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Description and details of the 26 antibodies used for cell lines characterization.
Antibody Dilution Time (h) Company
NG2 1:500 24 Millipore
A2B5 1:500 24 Millipore
β-III tubulin 1:1000 24 Abcam
MCM2 1:500 24 Abcam
8OHdG 1:250 24 Santa Cruz
NeuroD1 1:100 24 Abcam
Nestin 1:500 24 Millipore
Sox-2 1:100 24 R&D Systems
Sox-9 1:100 24 Abcam
GFAP 1:1000 24 Sigma Aldrich
DCX 1:1000 24 Santa Cruz
IGFR1 1:500 24 Cell Signaling
Prominin-1 1:100 24 Abcam
Calretinin 1:3000 24 Swant
Calbindin 1:500 24 Millipore
MCR 1:500 24 Santa Cruz
Arc 1:500 24 Santa Cruz
p35 1:500 24 Cell Signaling
LEF1 1:500 24 Abcam
GR 1:500 24 Abcam
mAB367 1:500 24 Millipore
AchE 1:500 24 Santa Cruz
AchRα7 1:500 24 Santa Cruz
AchRβ2 1:500 24 Santa Cruz
Glutamate R1 AMPA 1:500 24 Sigma Aldrich
PROX-1 1:500 24 Abcam
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than those treated with BCNU alone [6]. In addition, it has been
reported that DEXA induces apoptosis resistance in most solid
malignant tumors during co-treatment with chemotherapy agents
such as camptothecin (CAM) [6]. The beneﬁcial effects related to
the use of DEXA in patients with intracranial tumors have been
described extensively in the literature [2,12,13].
The DEXA effects have also been studied in other kinds of tu-
mors, mainly multiple myeloma (MM). Through this research, an
antimyeloma effect of DEXA has been partly elucidated as acting
via the induction of oxidative stress when DEXA is combined with
radiation [14]. This introduces a new paradigm for DEXA usage in
MM that can potentially be incorporated into the design of more
effective combined modality therapies [14]. Despite this, other
studies have shown that DEXA may confer radioresistance in dif-
ferent types of carcinoma [15,16].
In the speciﬁc case of brain tumors, different practical guides
exist regarding the use of DEXA [1]. In all cases, DEXA is used to
minimize neurological symptoms and treatment-related side-ef-
fects [17]. Although the best dosages have been established [1,18]
in the extended use of steroids in the treatment of brain tumors
[19,20], the molecular mechanisms that underlie their beneﬁcial
effects are not yet well established.
Interesting, a previous work in adult neurogenesis has eluci-
dated a new role of DEXA causing a decrease in the adult neural
stem cell (aNSC) pool, proliferation-dependent, within dentate
gyrus (DG) when DEXA was administered postnatally. Indeed,
DEXA negatively affected neuronal proliferation [30].
Taking all the data together, it is possible to highlight that de-
spite the clinical relevance of GCs in the co-treatment of cancer,
their role in combination with chemotherapy or radiation agents
have still not been well explored. In addition, there are multiple
questions remaining, as GCs do not act in the same way in all types
of cells or with all types of primary treatments (different che-
motherapeutic or radiation agents). For this reason, the current
work has been focused on clarifying the role of DEXA in the spe-
ciﬁc case of astrocytoma cell lines (CT2A, APP.PS1 L.1 and APP.PS1
L.3), looking particularly at DNA damage and repair as key me-
chanisms in the evolution of the cancer process. It was considered
essential to uncover whether DEXA itself may have a protective
effect against cancer in these cell types and whether combination
with irradiation (IR) could help solve the high proliferation present
by deﬁnition in the oncogenic process. To clarify the role of DEXA
in these processes, different mechanisms involved in DNA damage
and repair were studied after DEXA was administered in combi-
nation with IR or without it. In addition, this work provides a new
model for the mechanism by which DEXA may contribute to DNA
damage and subsequently cause cell death in three different kinds
of astrocytoma cell lines.Methods
Cell lines
Three astrocytoma cell lines were used. CT2A is a commercial
astrocytoma cell line. APP-PS1 L.1 and APP. PS1 L.3 are two dif-
ferent astrocytoma cell lines obtained from a mice APP.PS1 which
previously were injected with 20-methylcholantrene (a carcino-
gen) and which developed different kinds of astrocytoma tumors.
These three cell lines were a gift from Dr. Ricardo Martínez-Mur-
illo laboratory (Cajal Institute, Madrid, Spain). These cells were
maintained in RPMI medium (12633-012, Gibco) supplemented
with 10% fetal bovine serum (10,106-151, Gibco) and 5 mg/mL
penicillin/streptomycin (15070-063, Gibco).Cells were cultured in
a humidiﬁed incubator at 37 °C under 5% CO2 atmosphere.DEXA treatment
All treatments with DEXA were performed by incubating cells
with DEXA at 50 mM (D4902, Sigma-Aldrich, St. Louis, MO, USA).
Aliquots of 1 mg DEXA were resuspended in 1 mL of ethanol and
diluted in 49 mL culture medium [RPMI media (1640, Gibco)þ10%
Fetal Bovine Serum (10,106-151, Gibco)] to a ﬁnal concentration of
50 mM. 3 mL of this medium was used in DEXA conditions, and
3 mL of culture medium as the vehicle in control conditions.
Treatment was carried out at different times indicated in each
experiment.
Ionizing radiation
Cells were irradiated with 5 Gy (100 kV, 250 mA, 1 min) for all
experiments. The model of the irradiator used was the ´Smart 200
E" 85,034′, supplied by Cajal Institute.Experiments at Oxford
University were performed using their own irradiator (5 Gy was
the dose used).
Cell characterization
To characterize the cells, the 26 antibodies described in Table 1
were used.
Immunoﬂuorescence
The cells were plated on coverslips, irradiated with 5 Gy if in-
dicated, and collected at varying time intervals. At collection, the
cells were ﬁxed with 4% paraformaldehyde and 0.2% Triton X-100
in PBS for 20 min at RT, followed by 3 washes in PBS. After
blocking in 1% BSA and 0.1% Triton X-100 in PBS for 1 h at 37 °C,
the cells were incubated with 53BP1 (NB100-304, Novus Biologi-
cals), or Anti-phospho-Histone H2AX (Ser139) clone JBW301(05-
636, Millipore) antibodies (1:3000 dilution), overnight at 37 °C.
Three washes in PBS were carried out followed by incubation for
1 h at 37 °C with the appropriate secondary antibodies. The ﬁnal
1 8-OHdG antibody used was sc-66036. This antibody is recommended for
detection of 8-OHdG (8-hydroxy-2′-deoxyguanosine, 8-hydroxyguanine and
8-hydroxyguanosine).
S. Ortega-Martínez / Redox Biology 5 (2015) 388–397390washes in PBS were carried out, the cells were counterstained with
DAPI and coverslips were mounted on slides using gervatol
mounting medium. Fluorescent micrographs were taken using a
Nikon 90i upright microscope. These experiments were performed
in triplicate.
Kinetic experiment
The cells were plated overnight. They were irradiated with
5 Gy, and ﬁxed for different periods of time (30, 60, 210, 360 min).
The control conditions were not irradiated, only ﬁxed at the be-
ginning of the experiment. 53BP1 Foci were evaluated as in-
dicators of the non-homologous end-joining (NHEJ) pathway.
53BP1 Blocks resection of DNA ends resulting from damage in G1,
but its action is antagonized by BRCA1 in the S phase. γH2AX was
an indicator of double strand breaks (DSBs) and DNA damage.
These experiments were performed in triplicate.
IrradiationþDEXA experiments
The cells were plated in p60 overnight and then irradiated with
5 Gy. DEXA medium (50 mM) was added for the DEXA conditions,
while the mediumwas changed for vehicle conditions. The cells were
ﬁxed either 30 or 240min after irradiation. In control conditions,
culture medium or DEXA medium (50 mM) was added without irra-
diation. The control cells were ﬁxed after 240 min. 53BP1 foci and
γH2AX foci were evaluated. These experiments were performed in
triplicate.
IrradiationþDEXAþascorbic acid experiments
The cells were plated in p60 overnight and then irradiated with
5 Gy. DEXA medium (50 mM) was added for the DEXA conditions,
along with the combination of DEXA (50 mM) and ascorbic acid
(A4403, Sigma-Aldrich, St. Louis, MO, USA) in 0.05 mM con-
centration. In vehicle conditions, only the medium was changed.
The cells were ﬁxed either 30 or 240 min after IR. In control
conditions, culture medium, DEXA medium (50 mM), or a combi-
nation of DEXA (50 mM) and ascorbic acid (0.05 mM) were added,
without IR. The control cells were ﬁxed after 240 min. The γH2AX
foci were evaluated. These experiments were performed in tripli-
cate at Oxford University (Dr. Eric O'Neill's lab).
Neutral comet assay
Neutral comet assays were performed using CometSlide assay kits
(Trevigen). Cells were treated with either vehicle or DEXA for 2 h. The
cells were then irradiated with 5 Gy and incubated at 37 °C for dif-
ferent periods of time (0, 30, 60, 90 and 120min) to allow DNA da-
mage repair. The cells were embedded in agarose, lysed, and subjected
to neutral single cell gel electrophoresis. The agarose was dehydrated
and the cells were stained with 4′,6-diamidino-2-phenylindole (DAPI)
for visualization under a ﬂuorescence microscope. The olive comet
moment was determined using the software CometScore Version 1.5
(TriTek). The olive moment was calculated by multiplying the per-
centage of DNA in the tail and the difference between the means of
the head and tail distributions, as described [21]. A total of 50 comets
(and two replications) were analyzed per sample for each experiment.
These experiments were performed in triplicate.
Cell cycle experiments
1106 cells were plated in 1 cm2 plate with RPM1þ10% FBS. The
following day DEXA was added for 6 h. After, cells were washed with
PBS and centrifuged, and the pellet was ﬁxed in 70% ethanol in PBS
and conserved one day at 20 °C. The next day pellets cells wereresuspended in 0.5 mL PBS containing DAPI (1 mg/mL). The cell cycle
analysis was performed using a FACStar Plus (Becton, Dickinson).
30,000 Cells per condition (CT2A control, CT2A DEXA, APP-PS1 con-
trol, APP-PS1 DEXA, APP-PS1 L.3 control and APP-PS1 DEXA) were
evaluated in total.These experiments were performed at Leibniz In-
stitute for Age Research (Dr.Zhao-Qi Wang's lab), and repeated in tri-
plicate at Oxford University (Dr. Eric O'Neill's lab).
Time-lapse experiments
300,000 Cells per condition (CT2A control, CT2A DEXA, APP-PS1
control, APP-PS1 DEXA, APP-PS1 L.3 control and APP-PS1 DEXA) were
plated in 6-well plates and cultured with RPMIþ10% FBS. 3 Hours
after addition of DEXA for all DEXA conditions, beginning to register
the behavior of cells using time lapse microscopy over 24 hours in a
humidiﬁed incubator at 37 °C under a 5% CO2 atmosphere.
Survival experiments
350,000 Cells per condition (CT2A control, CT2A DEXA, APP-
PS1 control, APP-PS1 DEXA, APP-PS1 L.3 control and APP-PS1
DEXA) were plated in 6-well plates and cultured in an IncuCyte
microscope (in a humidiﬁed incubator at 37 °C under 5% CO2 at-
mosphere), with or without DEXA treatment for 3 days. Subse-
quently, the ﬁnal conﬂuence in these wells was evaluated using
the IncuCyte software. The experiment was evaluated in triplicate.
Statistical analysis
For all the experiments, a “two-tailed” student’s t-test or ANOVA
was used to calculate statistical signiﬁcance of the observed differ-
ences, using SPSS software or GraphPad Prism software. Furthermore,
for the neutral comet assay, a repeated measures ANOVA was per-
formed to evaluate the dexamethasone effect as a whole. Microsoft
Excel v.2010 was used for the calculations. In all cases, differences
were considered statistically signiﬁcant when po0.05.Results
Characterizing astrocytoma cell lines using a battery of twenty-six
different markers.
CT2A, is used in literature as a cell line of commercial astrocytoma.
APP. PS1 L.1 and APP.PS1 L.3, are two different cell lines, type astro-
cytoma obtained through APP-PS1 mice, and generated in the la-
boratory of Dr. Ricardo Martinez-Murillo (Department of Neuroa-
natomy and Cell Biology, Instituto Cajal, CSIC, Avenida del Doctor Arce
327, 28,002 Madrid, Spain). An analysis was performed to characterize
these cell lines by employing 26 different markers (Table 1). The re-
sults obtained are described in Fig. 1. Most of the markers analyzed
were present in all cell lines. It is important to highlight the presence
of the glucocorticoid receptor (GR) and the mineralocorticoid receptor
(MR) in the three cell lines, suggesting that they are susceptible to
glucocorticoid and mineralocorticoid action.
By contrast, the main differences found are shown correspond
to Acetylcholine Receptor Alpha 7 (AchRα7), Glial Fibrillary Acidic
Protein (GFAP) and 8-hydroxydeoxyguanosine (8-oHdG1). In the
case of AchRα7, the differences found are that this receptor was
present in CT2A and APP.PS1 L.1 but it was not present in APP.PS1
L.3. This receptor has been implicated in a lot of process as an
Fig. 1. Summary of results for the characterization of these cell lines. 1A. Table indicating results obtained which each antibody. ¿?Indicates that immunostaining did not
reveal a sufﬁciently good labeling to make a reliable conclusion. N.F. indicates that the antibody did not work. 1B. Example of the immunoﬂuorescence obtained in some
relevant antibodies.
S. Ortega-Martínez / Redox Biology 5 (2015) 388–397 391essential regulator of inﬂammation [22], and currently has been
described its role in neuroprotection [23]. Besides CT2A and APP.
PS1 L.1 also shared the expression of GFAP, which is not found in
the APP.PS1 L.3 cell line. This marker is present in neural stem cells
(NSCs) and glial cells, but not in neurons. Finally, there was nopresence of the marker 8-hydroxy-2′-deoxyguanosine (8-OHdG)
in CT2A while this marker was present in astrocytomas cell lines
which were obtained from mice APP.PS1 (L.1 and L.3). 8-OHdG is a
biomarker of oxidative stress to DNA and a risk factor for cancer,
atherosclerosis and diabetics [24]. The cytoplasmic ﬁne granular
S. Ortega-Martínez / Redox Biology 5 (2015) 388–3973928-OHdG expression was considered to reﬂect 8-OHdG-positive
mitochondrial DNA affecting oxidation stress [25]. The lack of
presence of this market is relevant because it suggests that the
CT2A cell line does not exhibit oxidative stress as a phenotypically
intrinsic cell characteristic (see Fig. 1B).Fig. 2. Foci formation and disappearance. 2A. Percentage of γH2AX-positive cell foci o
immunoﬂuorescence of kinetic experiment, analyzing the formation and disappearance o
the Irradiation þ dexamethasone condition. 2E. Evaluation of γH2AX foci in the Irradi
(p ¼ 0.011); APP.PS1 L.1 w/o IR (p ¼ 0.040), DEXA IR 240′ (p ¼ 0,000); APP.PS1 L.3 DEEvaluating the kinetics of the formation and disappearance of γ-H2AX
and 53BP1 foci in astrocytoma cell lines following irradiation (IR).
It is known that following irradiation, cells initiate processes to
repair the damage, and at that time it is possible to observe thever time. 2B. Percentage of 53BP1-positive cell foci over time. 2C. Example of the
f γ-H2AX and 53BP1 foci. Objective 40x. 2D. Evaluation of 53BP1 foci by cell lines in
ation þ dexamethasone condition. CT2A: DEXA w/o IR (p ¼ 0.049), DEXA IR 240′
XA IR 240′ (p ¼ 0,044).
Fig. 3. (A) Neutral comet assay graph obtained for the three cell line with and without IR. CT2A DEXA 30′ (p¼0.031), 60′ (p¼0.033), 90′ (p¼0.012), 120′ (p¼0.052). Repeated
measures test comparing Control to DEXA in CT2A (p¼0.001). App. PS1 L.1 DEXA 30′ (p¼0.036). Repeated measures test comparing Control to DEXA in APP.PS1 L.1
(p¼0.022). App. PS1 L.3 DEXA 30′ (p¼0.023). Repeated measures test comparing Control to DEXA in APP.PS1 L.3 (p¼0.028). (B) Cell cycle analysis in three astrocytoma cell
lines. No differences in cell phases were observed between Control and DEXA conditions in any cell line 3C. Proliferation and cell death experiment. Evolution of each cell line
under Control and DEXA conditions after 24 h. Objective 10 .
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length of time, these cells recover their normal state and the foci
are no longer present. This time varies depending on the cell line.
For that reason, this study aimed to evaluate the baseline process
of γ-H2AX and 53BP1 foci formation and disappearance, for later
comparison with the different treatment conditions. In all cases,
the percentage of γ-H2AX was used as a measure of DNA damage,
and the 53BP1 foci was used as a measure of DNA repair by the
NHEJ pathway. To determine whether a cell was positive for the
presence of foci, it was determined that cells must present at least
ﬁve foci. When the cells showed a smaller number of foci, they
were considered negative.
In this experiment, statistical analysis comparing the different
cell lines have not been performed since the main goal of the
experiment was to evaluate how each cell line responds to the IR,
and how the kinetics of the formation and disappearance of the
foci is. The results showed, in general, that without IR all cell lines
had a background of fociþcells (53BP1 as well as γ-H2AX) in the
ratio 10–15%. 30–60 Min after IR all cell lines increased its per-
centage of fociþcells, which decrease when it was evaluated
210 min after IR. Then, after 6 h of IR all cell lines presented the
initial background of fociþcells (Fig. 2A and B). An example of the
immunoﬂuorescence of CT2A cell line is represented in Fig. 2C.
Evaluating the kinetics of the formation and disappearance of γ-H2AX
and 53BP1 foci, in astrocytoma cell lines after IR, with or without
subsequent addition of glucocorticoid (DEXA, 50 mM).
This experiment aimed to evaluate the effect of GCs, speciﬁcally
DEXA 50 mM, administered immediately after the IR. For this
purpose, the effect in Control conditions without irradiation was
ﬁrst evaluated. In all cases, the percentage of γ-H2AX was used as
a measure of DNA damage, and 53BP1 foci as a measure of DNA
repair by the NHEJ pathway.
DEXA did not produce any consequence in 53BP1 foci, and
there were no signiﬁcant differences between Control and DEXAconditions when these foci were evaluated in any cell line
(Fig. 2D). On the other hand, when γ-H2AX foci were evaluated
(Fig. 2E), there were signiﬁcant differences between Control and
DEXA in conditions without irradiation in CT2A (p¼0.049) and
APP.PS1 L.1 (p¼0.040), and in all cell lines when the cells were
irradiated and γ-H2AX foci were evaluated 4 h after the IR (CT2A
p¼0.011; APP.PS1 L.1 p¼0.000; APP.PS1 L.3 p¼0.054). There were
no signiﬁcant differences when the cells were irradiated and γ-
H2AX foci were evaluated 30 min following IR (CT2A p¼0.079;
APP.PS1 L.1 p¼0.702; APP.PS1 L.3¼0.955).
Analyzing the DNA damage repair kinetics in Control conditions and
with addition of DEXA, in astrocytoma cell lines using the neutral
comet assay technique.
The purpose of this experiment was to evaluate the kinetics of
DNA repair using the neutral comet assay, a technique that ana-
lyzes unrepaired DNA over time as a measure of the olive moment,
calculated using CometScore software as explained above. In order
of evaluate the possible signiﬁcance of any differences, the sta-
tistical software SPSS was used, and student's t-tests were per-
formed for Control and DEXA conditions at each time evaluated. In
addition, a repeated measures ANOVA was used to evaluate the
DEXA effect as a whole.
The results obtained from the kinetic curves show that there
were signiﬁcant differences in the three cell lines, between Control
and DEXA treatment, by repeated measures ANOVA (CT2A
p¼0.001; APP.PS1 L.1 p¼0.022; APP.PS1 L.3 p¼0.028). Evaluating
the differences between treatments at each time point, in all cell
lines there were signiﬁcant differences between Control vs DEXA
treatment at 30 min (CT2A p¼0.031; APP.PS1 L.1 p¼0.036; APP.
PS1 L.3 p¼0.023), corresponding to the phase in which the DNA is
repaired faster and more effectively via the NHEJ pathway. In the
other times (60, 90 and 120 min) were not found any signiﬁcant
differences between treatments (Control vs DEXA) in APP.PS1 L.1
and APP.PS1 L.3 cell lines, although DEXA condition presents
S. Ortega-Martínez / Redox Biology 5 (2015) 388–397394always higher levels of DNA unrepaired compared to Control
condition. By contrast CT2A cell line presented signiﬁcant differ-
ences in all times analyzed: 60 min (p¼0.033); 90 min (p¼0.012),
and a trend toward signiﬁcance (represented by # in Fig. 3A) at
120 min (p¼0.052). In all cases, the DEXA condition presented
higher levels of unrepaired DNA compared to Control conditions
(Fig. 3A).Analyzing DEXA effects in cell cycle proﬁle in astrocytoma cell lines.
This experiment was used to evaluate if DEXA causes or not a
problem in the progression of the cells through cell cycle. In all
cases, DEXA did not produce any change in the cell cycle proﬁle
compared to Control condition suggesting DEXA does not produce
an arrest any cell cycle phases (Fig. 3B).Fig. 4. Ascorbic acid experiment. (A) Immunoﬂuorescence of ascorbic acid experiment,
alone and DEXAþascorbic acid (AA). Arrows indicate γH2AX-positive cell foci. Objective
DEXA and DEXA þ ascorbic acid). CT2A DEXA w/o IR (p¼0.046), IRþ240 (p¼0.025). AAnalyzing cell survival in Control and DEXA conditions using an In-
cucyte microscope.
The Incucyte microscope was used to evaluate the conﬂuence
of cells over time, along with the DEXA effect in astrocytoma
cultures. In all cases, DEXA was added at the beginning of the
experiment. The results obtained were similar in the three cell
lines used. Thus in the Control condition, cells grew over time until
reaching conﬂuence. In the DEXA condition, the Incucyte micro-
scope was able to detect cell death over time.
Determining the existence of cell death or cell proliferation with and
without the addition of DEXA in the astrocytoma cell lines by time-
lapse microscopy.
The goal of this experiment was to determine whether cellanalyzing the formation and disappearance of γ-H2AX foci after addition of DEXA
40 . (B) Percentage of γH2AX-positive cell foci in the different conditions (control,
pp. PS1 L.1 DEXA IR þ 240 (p¼). App. PS1 L.3 DEXA IR þ 240 (p¼0.014).
S. Ortega-Martínez / Redox Biology 5 (2015) 388–397 395death or cell proliferation occurred over time via time-lapse mi-
croscopy. Control and DEXA-treated cells were monitored every
5 min for 24 hours. The results were similar in three cell lines and
show that the DEXA conditions mainly produced cell death, while
the Control conditions showed cell proliferation (Fig. 3C). An ex-
ample of the CT2A cell line time lapse are shown in video 1
(Control condition) and 2 (DEXA condition).
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.redox.2015.06.
006.
Potential of ascorbic acid to reverse the DEXA/IR-induced γ-H2AX foci.
To analyze whether the increase in the γ-H2AX foci with DEXA
treatment could be reversed, ascorbic acid, an agent that recruits
free radicals, was used in a concentration of 0.05 mM. The for-
mation of γH2AX foci without IR and 4 h after the IR were de-
termined in both treatment conditions. Results obtained from each
cell line are explained (Fig. 4): CT2A: DEXA alone produced an increase in the number of
γH2AX fociþcells without IR (p¼0.046) and 4 h following IR
(p¼0.025). However, when ascorbic acid was added to the
DEXA condition, the levels of fociþcells returned to baseline
(Fig. 6A and B). This result suggests that DEXA may increase
γH2AX foci levels via oxidative stress induced augmentation of
free radicals. APP. PS1 L.1: DEXA produced an increase in the number of
γH2AX fociþcells in the condition 4 h following IR (p¼0.014).
The increase levels of γH2AX foci that occur in the DEXA con-
dition was reversed by adding ascorbic acid, suggesting again
that DEXA could exert their action through the increase of free
radical. APP. PS1 L.3: DEXA only produced an increase in γH2AX foci
levels in the 4 h after IR condition (p¼0.014). Similar to the
results obtained in other cell lines, said increase was reversed
by adding ascorbic acid, suggesting that DEXA exerts its action
by increasing levels of free radicals.Discussion
The main goal of the present work was to elucidate the effects
of DEXA (glucocorticoid) in the speciﬁc case of three different
astrocytoma cell lines in the context of DNA damage and repair.
This premise is essential because the use of GCs is widespread as
co-treatment with chemotherapy and radiotherapy for many tu-
mors, including those of the central nervous system [9,10], but
how these GCs act in processes such as DNA damage and repair –
essential steps in the oncogenic process – remain largely
unknown.
A multitude of DNA damage and repair pathways could be
crucial as diverse as the progression of cells that have the ability to
cause cancer. It is logical to consider that in the oncogenic pro-
cesses, the mechanisms underlying DNA damage and repair may
be altered, conferring upon these cells the difference between the
normal and pathological state. There have been many investiga-
tions aimed at studying the role of the DDR, or different molecules
involved in it, in astrocytoma or glioblastoma cell lines. These
studies have been designed, for example, to evaluate the effect of
IR on those cell lines [26,27], having as an ultimate goal the elu-
cidations of the mechanisms underlying this type of tumor ther-
apy [28]. The present work has focused on gaining a better basic
understanding of the key processes governing the DDR in three
astrocytomas cell lines because one of the main problems in thetreatment of brain tumors lies in their extreme diversiﬁcation. For
that reason, their characterization is an important key for devel-
oping further treatment. Likewise, the study wanted to examine
the effects of GCs, speciﬁcally DEXA, as such molecules could play
a key role in the DNA damage and repair. DEXA is used in the co-
treatment of brain tumors, mainly for its anti-inﬂammatory effects
[2,9,17,19]; however, it may have another relevance that has yet to
be described.
To achieve these goals, the ﬁrst step was to characterize these
cell lines using twenty-six different markers. While most of the
markers analyzed were present in the three cell line, one im-
portant result was the absence of the marker 8-hydroxy-2-deox-
yguanosine (8-OHdG) just in the case of CT2A cell line while it was
present in cell obtained from APP.PS1 mice. This marker is crucial
[24] because it indicates that there is no oxidative stress mediated
DNA background damage in the CT2A cell line. Other important
results, such as the presence of both kinds of steroid receptors
(glucocorticoid receptor (GR) and mineralocorticoid receptor
(MR)) show that these cell lines are susceptible to the actions of
both steroids.
These results are relevant, because they reveal a genetic back-
ground that might be involved in how these cells behave with IR,
drugs or the DNA-repair pathways. The biological signiﬁcance of
these data are the importance of characterizing tumors. These
phenotypic characteristics for speciﬁc tumors could be crucial in
establishing better therapies. This means that different kinds of
tumors may not show the same therapeutic response to treatment.
Another goal was to highlight how a glucocorticoid, speciﬁcally
DEXA, could inﬂuence DNA damage and repair mechanisms. One
of the key experiments consisted subjecting astrocytoma cells to a
pulse of IR, and then evaluating the evolution of two types of foci
(gamma-H2AX and 53BP1) in the absence or presence of DEXA
(see Fig. 2D and E). On one hand, DEXA did not seem to inﬂuence
the formation and persistence of 53BP1 foci in any of the cell lines
studied (see Fig. 1D), meaning that, in principle, it does not in-
ﬂuence the NHEJ repair pathway at the level of that speciﬁc pro-
tein. On the other hand, an increase in the basal levels of the
gamma-H2AX foci was observed without IR in CT2A and APP.PS1
L.1 (see Fig. 2E). This is extremely signiﬁcant because it means that
DEXA can, by itself, cause DNA damage in some astrocytoma cells.
This result could impact the therapeutic implications of DEXA in
the treatment of brain tumors, emphasizing the importance of
further studies of this effect. Moreover, the DEXA produced higher
levels of gamma-H2AX foci for a longer time, 4 hours after IR,
while in Control conditions, the gamma-H2AX foci had already
returned to nearly basal levels. This result, obtained in all cell lines
analyzed, is of great relevance, since it shows that DEXA can in-
crease DNA damage in the astrocytoma cells for a longer period of
time when combined with IR.. These data have future biological
implications, because GCs may not only act as anti-inﬂammatory
molecules in the treatment of tumors, but they might also inﬂu-
ence the mechanisms underlying DNA damage and repair, as key
mechanisms in the evolution of oncogenic processes.. This ﬁnding
is really exciting, as it suggests that DEXA could promote radio-
sensitivity in brain tumors.
The neutral comet assay was used to analyze whether DEXA
indeed changes the kinetics of DNA repair. The results obtained
show that DEXA administered 2 hours before IR led to a radical
change in the kinetics of the DNA repair curve in all astrocytoma
cell lines (see Fig. 3A). The ﬁrst phase of the comet assay corre-
sponding to the fast track of DNA repair by NHEJ was much less
pronounced, and the slow HR repair phase was also modiﬁed. The
overall result was that DEXA indeed exerted an effect upon both
DNA repair pathways. The ability of DEXA to impact DNA repair
kinetics following IR suggests that this drug could potentially be
used as a radiosensitizer, although future experiments are needed
Fig. 5. Model proposal for one of the DEXA mechanism of action, causing DNA damage, via oxidative stress.
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In addition, it was important to assess whether or not DEXA
produces impairments in cell proliferation or cell death in astro-
cytoma cell cultures of these three cell lines. The ﬁndings shown in
Fig. 3C demonstrate that DEXA caused a decrease in normal cell
proliferation, compared with Control conditions. At the same time,
DEXA caused an increase in cell death, leading to very low con-
ﬂuence in the cell cultures. DEXA also acts by promoting apoptosis,
as has been previously described in different kinds of cell cultures
[1,17,18]. Consistent with the fact that DEXA produced cell death
are cell cycle results, concluding that DEXA did not produce an
arrest in any phase of the cell cycle (see Fig. 3B).
After the evaluation of the DEXA effects in terms of increased
DNA damage (seen by the increase in γ-H2AX foci levels), impaired
DNA repair kinetics, and cell death in the three cell lines cultures,
it was important to analyze the possible mechanisms of action by
which DEXA could be exerting its effects. The hypothesis was that
the drug might be increasing free radicals via oxidative stress, as
has been demonstrated in previous studies [2,19]. This in turn
could cause an increase in DNA damage. In order to test this hy-
pothesis, ascorbic acid was used, as it has been shown in the lit-
erature to reduce the production of reactive oxygen species (ROS)
[29]. The results show that, in fact, when cells were irradiated,
addition of DEXA and ascorbic acid led to the return of gamma-
H2AX foci to basal levels, suggesting that at least one of the me-
chanisms of DEXA in the DNA damage pathway is increasing ROS,
which would in turn lead to an increase in the levels of gamma-
H2AX foci (Fig. 4). This result is relevant because it give us a better
means to investigate how glucocorticoids act in the speciﬁc case of
astrocytoma cell lines. In this regard, this work has proposed a
new model for the mechanism of action by which DEXA causes
DNA damage, with higher levels of gamma-H2AX foci observed
(see Fig. 5).Conclusions
Taken together, the data presented here establish the im-
portance of looking at the role of GCs as an adjuvant in thetreatment of brain tumors, in particular astrocytomas, since this
study has demonstrated that they play a key role in increasing
DNA damage (seen by higher persistence of gamma-H2AX foci
levels) produced by cancer therapies such as IR. At the same time,
it is established that DEXA itself cause cell death in astrocytoma
cell cultures, as well as producing impairments in the DNA repair
pathways, even does not cause arrest in any of the cell cycle
phases. Finally and most importantly, this work has elucidated at
least one of the mechanisms of action by which DEXA acts: the
increase of free radicals in astrocytoma cell cultures via oxidative
stress. In that sense, this work marks an important starting point
in research regarding a new model of GCs action in the treatment
of brain tumor therapies, with all of the future therapeutic im-
plications that includes.Authors’ contributions
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